Amylmetacresol is a synthetic antimicrobial agent that is a mixture of isomers of 4-methyl-2-(1-methylpropyl)phenol. It is used as a topical antiseptic and is effective against a wide range of bacteria, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Amylmetacresol is also effective against fungi and viruses. It is commonly found in over-the-counter throat lozenges and mouthwashes. It has been studied for its potential use in treating otitis media, sinusitis, and other infections. Amylmetacresol is generally well-tolerated but can cause side effects such as skin irritation and allergic reactions. It is also not recommended for use in children under 2 years of age.'
amylmetacresol: topical antiseptic for treatment of sore throat; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
amylmetacresol : A phenol having the structure of m-cresol substituted at the 6-position with an amyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 14759 |
| CHEMBL ID | 1512677 |
| CHEBI ID | 48213 |
| SCHEMBL ID | 302197 |
| MeSH ID | M0538347 |
| Synonym |
|---|
| amilmetacresol |
| 3-06-00-02005 (beilstein handbook reference) |
| unii-05w904p57f |
| 05w904p57f , |
| amylmetacresol [inn:ban] |
| brn 2440952 |
| m-cresol, 6-pentyl- |
| amylmetacresolum [latin] |
| phenol, 5-methyl-2-pentyl- |
| amilmetacresol [spanish] |
| einecs 215-094-0 |
| NCGC00180998-01 |
| amylmetacresol |
| 6-n-amyl-m-cresol |
| 6-amyl-m-cresol |
| 6-pentyl-m-cresol |
| 6-n-pentyl-m-cresol |
| CHEBI:48213 , |
| amylmetacresolum |
| 5-methyl-2-pentylphenol |
| 1300-94-3 |
| dtxcid6026791 |
| dtxsid8046791 , |
| cas-1300-94-3 |
| tox21_112651 |
| CHEMBL1512677 |
| AKOS015912095 |
| S6173 |
| FT-0620948 |
| SCHEMBL302197 |
| 6-n-amyl-m-cresol [mi] |
| amylmetacresol [who-dd] |
| amyl metacresol |
| amylmetacresol [inn] |
| amylmetacresol [ep monograph] |
| amyl metacresol [vandf] |
| amylmetacresol [ep impurity] |
| amylmetacresol [vandf] |
| amylmetacresol [mart.] |
| W-108357 |
| 5-methyl-2-n-pentylphenol , |
| STL453583 |
| 5-methyl-2-n-pentylphenol, aldrichcpr |
| mfcd00127710 |
| SR-01000944860-1 |
| sr-01000944860 |
| amylmetacresol; 5-methyl-2-pentylphenol |
| 2-amyl-5-methylphenol |
| DB13908 |
| DS-15450 |
| Q1946346 |
| amylmetacresol 100 microg/ml in acetonitrile |
| HY-121527 |
| A888790 |
| BAA30094 |
| CS-0082471 |
| EN300-7404783 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Role | Description |
|---|---|
| antiseptic drug | A substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| USP1 protein, partial | Homo sapiens (human) | Potency | 35.4813 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 26.8325 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720719 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 33.4915 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 23.7101 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 26.6032 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 33.4915 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (76.31) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (27.27%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (63.64%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||